✉ Email this page to a colleague
« Back to Dashboard
▶ Start for $1
Remove trial restrictions
PF-06463922 is an investigational drug.
There have been 16 clinical trials for PF-06463922. The most recent clinical trial was a Phase 1 trial, which was initiated on December 31st 2021.
The most common disease conditions in clinical trials are Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, and Lymphoma. The leading clinical trial sponsors are Pfizer, Clinical research technology Srl, and Fondazione Ricerca Traslazionale.
There are twenty-one US patents protecting this investigational drug and two hundred and ninety-eight international patents.
Recent Clinical Trials for PF-06463922
|Study to Evaluate the Effect of Hepatic Impairment on the Pharmacokinetics and Safety of Lorlatinib||Pfizer||Phase 1|
|Lorlatinib Continuation Study||Pfizer||Phase 4|
|PF-07284892 in Participants With Advanced Solid Tumors||Pfizer||Phase 1|
Top disease conditions for PF-06463922
Top clinical trial sponsors for PF-06463922
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|PF-06463922||See Plans and Pricing||Substituted macrocycles useful as kinases inhibitors and methods of use thereof||Teligene Ltd. (Suzhou, CN)||See Plans and Pricing|
|PF-06463922||See Plans and Pricing||Nucleic acid encoding a humanized anti-BCMA chimeric antigen receptor||Novartis AG (Basel, CH) The Trustees of the University of Pennsylvania (Philadelphia, PA)||See Plans and Pricing|
|PF-06463922||See Plans and Pricing||CD20 therapies, CD22 therapies, and combination therapies with a CD19 chimeric antigen receptor (CAR)-expressing cell||Novartis AG (Basel, CH) The Trustees of the University of Pennsylvania (Philadelphia, PA)||See Plans and Pricing|
|PF-06463922||See Plans and Pricing||Treatment of cancer using anti-CD19 Chimeric Antigen Receptor||The Trustees of the University of Pennsylvania (Philadelphia, PA) Novartis AG (Basel, CH)||See Plans and Pricing|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|PF-06463922||China||CN107207528||2034-08-20||See Plans and Pricing|
|PF-06463922||European Patent Office||EP3183256||2034-08-20||See Plans and Pricing|
|PF-06463922||Japan||JP2017525716||2034-08-20||See Plans and Pricing|
|PF-06463922||Japan||JP6609308||2034-08-20||See Plans and Pricing|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|